ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

A growing body of evidence suggests that aggregated α-synuclein, the major constituent of Lewy bodies, plays a key role in the pathogenesis of Parkinson's disease and related α-synucleinopathies. Immunotherapies, both active and passive, against α-synuclein have been developed and are promising...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Eva Nordström, Fredrik Eriksson, Jessica Sigvardson, Malin Johannesson, Alex Kasrayan, Martina Jones-Kostalla, Paulina Appelkvist, Linda Söderberg, Patrik Nygren, Magdalena Blom, Adeline Rachalski, Karin Nordenankar, Olof Zachrisson, Ebba Amandius, Gunilla Osswald, Mikael Moge, Martin Ingelsson, Joakim Bergström, Lars Lannfelt, Christer Möller, Marco Giorgetti, Johanna Fälting
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Parkinson's disease
α-Synuclein
Humanized monoclonal antibody
Immunotherapy
Clinical development
ABBV-0805
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Acceso en línea:https://doaj.org/article/707d9ab628d84f509f885d36c2242dcb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/707d9ab628d84f509f885d36c2242dcb

Ejemplares similares